Press Releases

MD Anderson Cancer Center Orlando Is Now Also Enrolling Patients BETHESDA, Md., September 24, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the MD Anderson Cancer Center Orlando has become the second site participating in the Phase I/II clinical trial of DCVax-Direct, the Company’s next generation... Read More

Rapid Approval Of Three Minor Amendments; Trial To Proceed At More Than 20 Sites and First Draws On The $5.5 Million German Grant To Begin BETHESDA, MD, September 17, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the German regulatory authority (the Paul Ehrlich Institute, or PEI) has approved the... Read More

Capital Costs And Manufacturing Time Reduced; Potency And Purity Increased BETHESDA, MD, September 10, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been issued another key U.S. patent (#8,518,636) covering a next generation process for manufacturing lower cost human dendritic cells of both a higher... Read More

BETHESDA, Md., August 9, 2013 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on August 8, 2013, it entered into an agreement with institutional investors, including an existing healthcare focused institutional investor and a dedicated healthcare mutual fund for a registered direct placement of $15 million of... Read More

Three Adjustments To Be Made, Not Affecting Bases For Seeking Product Approval BETHESDA, MD, August 9, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company’s Phase III clinical trial... Read More